Compare GSK plc (GSK) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Marqeta Inc — how do they compare? GSK plc trades at $52.69 (market cap $101.34B), while Marqeta Inc trades at $17.7 (market cap $1.83B). The key difference: GSK plc is far larger — about 55.4× Marqeta Inc's market cap, and GSK plc pays a 3.49% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| GSK | MQ | |
|---|---|---|
Market Cap | $101.34B | $1.83B |
Sector | Health | Technology |
52-Week High | $61.18 | $27.32 |
52-Week Low | $36.20 | $15.04 |
Enterprise Value | $121.95B | $1.13B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Marqeta (MQ) trades at $17.63, up 9.3% in the last session, with a bullish technical outlook and a consensus price target of $19.00. The company reported mixed quarterly earnings, beating expectations in Q1 2026 but missing in Q4 2025. Revenue has stabilized around $625 million in 2025 after declines from 2022-2024, while net income remains negative. A 4:1 reverse stock split was effective July 1, 2026, to boost the share price. Operating cash flow improved significantly to $162.62 million in 2025.
The outlook is cautiously optimistic with analyst support but high valuation multiples pose risks. Investment opportunities include potential earnings growth and European expansion, while risks involve thin profit margins, competitive pressures, and ongoing profitability challenges. The stock's technical strength and positive sentiment may drive short-term gains, but fundamental improvements are needed for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
